- PaxMedica is developing PAX-101, which utilizes the company’s proprietary source of suramin sodium, for the treatment of ASD (Autism Spectrum Disorder)
- There is no FDA-approved treatment for the core symptoms of autism, even though the rates of autism spectrum disorder have jumped significantly from 2000 to 2020
- ASD is characterized by deficits in social communication, restricted and repetitive patterns of behavior, and significant impairment in functioning, three core aspects of the disease that PaxMedica aims to address
- The company announced positive topline results from a Phase 2 study evaluating PAX-101 as a potential treatment for ASD and hopes to replicate these results in a larger trial, for which PaxMedica is preparing
In the U.S., the rates of autism spectrum disorder (“ASD”), a diverse group of early-onset and lifelong neurodevelopmental conditions, have more than quadrupled from 2000 to 2020, according to data published by the Centers for Disease Control and Prevention (“CDC”) (https://ibn.fm/fRYhj). Researchers attribute the increase to advances in diagnostic capabilities as well as greater understanding and awareness of ASD (https://ibn.fm/v6gtI). PaxMedica (NASDAQ: PXMD) is a clinical-stage biopharmaceutical company intent on developing novel anti-purinergic therapies (“APTs”) for the treatment of ASD and other serious conditions.
Estimates from the CDC’s Autism and Development Disabilities Monitoring (“ADDM”) Network, which pools data from multiple sites across the United States, showed that about 1 in 36 children had been identified with ASD in 2020, up from 1 in 150 in 2000. Correspondingly, the combined prevalence per…
NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN